CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | quaternary nitrogen compound |
|
Accession: | CHEBI:26469
|
browse the term
|
Definition: | A nitrogen molecular entity that is electronically neutral but which contains a quaternary nitrogen. |
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
EXP |
Carnitine results in increased expression of ADIPOQ protein |
CTD |
PMID:30256492 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:29186614 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Carnitine promotes the reaction [Paraquat deficiency inhibits the reaction [Paraquat promotes the reaction [APP protein binds to APP protein]]] |
CTD |
PMID:33290254 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression multiple interactions |
EXP |
Carnitine results in decreased expression of BAX protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in decreased expression of BAX protein] |
CTD |
PMID:29186614 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbox1 |
gamma-butyrobetaine hydroxylase 1 |
multiple interactions increases chemical synthesis |
ISO |
Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Ketoglutaric Acids inhibits the reaction [Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]; Ketoglutaric Acids inhibits the reaction [Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]] |
CTD |
PMID:21439360 |
|
NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases phosphorylation |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of BCL2 protein]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of BCL2 mRNA] |
CTD |
PMID:23213347 PMID:29186614 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Gentamicins results in decreased expression of BCL2L1 protein] |
CTD |
PMID:19491382 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
Carnitine inhibits the reaction [Gentamicins results in increased cleavage of CASP3 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP3 mRNA]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of CASP3 mRNA]] Carnitine inhibits the reaction [quinone results in increased activity of CASP3 protein] |
CTD |
PMID:19491382 PMID:23213347 PMID:26562095 PMID:32478940 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [quinone results in increased activity of CASP8 protein] |
CTD |
PMID:32478940 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP ISO |
Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP9 mRNA] Carnitine inhibits the reaction [quinone results in increased activity of CASP9 protein] |
CTD |
PMID:23213347 PMID:32478940 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Diethylnitrosamine results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of CAT mRNA] |
CTD |
PMID:16889571 PMID:19294768 PMID:23213347 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Sunitinib results in increased expression of CCN2 mRNA] |
CTD |
PMID:26581635 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CDH1 protein] |
CTD |
PMID:28973641 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of COL1A1 mRNA]; Carnitine inhibits the reaction [Sunitinib results in increased expression of COL1A1 mRNA] |
CTD |
PMID:26581635 PMID:28973641 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
EXP |
[COL2A1 protein co-treated with Freund's Adjuvant] affects the abundance of Carnitine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine] |
CTD |
PMID:24709313 |
|
NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
EXP ISO |
valproyl-coenzyme A inhibits the reaction [CPT1A protein results in increased metabolism of Carnitine] [Doxorubicin co-treated with Carnitine] results in increased expression of CPT1A mRNA; [Genistein co-treated with Carnitine] results in increased expression of CPT1A protein; Carnitine inhibits the reaction [quinone results in decreased expression of CPT1A protein] |
CTD |
PMID:16283381 PMID:16362726 PMID:19854160 PMID:32478940 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
multiple interactions |
ISO |
Carnitine promotes the reaction [[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate] |
CTD |
PMID:21816645 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB mRNA]; Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB protein] |
CTD |
PMID:26581635 |
|
NCBI chr X:13,360,583...13,392,517
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Atrazine results in decreased expression of CYP17A1 mRNA] |
CTD |
PMID:29710542 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
Carnitine promotes the reaction [Ethanol results in increased expression of CYP2E1 protein] |
CTD |
PMID:8130774 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Doxorubicin results in decreased expression of FABP3 mRNA] |
CTD |
PMID:20470772 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fabp9 |
fatty acid binding protein 9 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 protein] |
CTD |
PMID:33965443 |
|
NCBI chr 2:91,591,842...91,595,873
Ensembl chr 2:91,592,298...91,595,873
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in decreased expression of FSHB protein] |
CTD |
PMID:33965443 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Ifosfamide results in decreased expression of GPX1 mRNA] |
CTD |
PMID:23213347 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
multiple interactions |
ISO |
Carnitine inhibits the reaction [quinone results in decreased expression of HADHA protein] |
CTD |
PMID:32478940 |
|
NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869
|
|
G |
Hrk |
harakiri, BCL2 interacting protein |
multiple interactions |
ISO |
Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK mRNA]; Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK protein] |
CTD |
PMID:16239342 |
|
NCBI chr12:38,387,484...38,409,652
|
|
G |
Hspa2 |
heat shock protein family A (Hsp70) member 2 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Cadmium Chloride results in increased expression of HSPA2 protein] |
CTD |
PMID:22359436 |
|
NCBI chr 6:95,128,504...95,131,281
Ensembl chr 6:95,128,350...95,131,287
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Carnitine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in decreased expression of IL10 protein]; Carnitine inhibits the reaction [Sunitinib results in decreased expression of IL10 mRNA] |
CTD |
PMID:26581635 PMID:33965443 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of IL1B mRNA]]; Carnitine inhibits the reaction [sunitinib results in increased expression of IL1B mRNA] |
CTD |
PMID:26562095 PMID:26581635 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in increased expression of IL6 protein]; Carnitine inhibits the reaction [Sunitinib results in increased expression of IL6 mRNA] |
CTD |
PMID:26581635 PMID:33965443 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lepr |
leptin receptor |
affects abundance |
ISO |
LEPR affects the abundance of Carnitine |
CTD |
PMID:20567778 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in decreased expression of LHB protein] |
CTD |
PMID:33965443 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [sunitinib results in decreased expression of MMP9 mRNA] |
CTD |
PMID:26581635 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases activity |
EXP |
[Carboplatin co-treated with Carnitine deficiency] results in increased expression of MPO protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased activity of MPO protein] |
CTD |
PMID:18597074 PMID:18852009 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
multiple interactions |
ISO |
Carnitine inhibits the reaction [nickel chloride results in decreased expression of COX1 mRNA] |
CTD |
PMID:21419151 |
|
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt-nd6 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6 |
multiple interactions |
ISO |
Carnitine inhibits the reaction [nickel chloride results in decreased expression of ND6 mRNA] |
CTD |
PMID:21419151 |
|
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Stavudine results in decreased expression of MTTP mRNA] |
CTD |
PMID:18299183 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in increased expression of NOS2 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of NOS2 mRNA] |
CTD |
PMID:23213347 PMID:33965443 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases expression |
EXP |
Carnitine results in increased expression of NOS3 |
CTD |
PMID:20123095 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Ocln |
occludin |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in decreased expression of OCLN protein] |
CTD |
PMID:33965443 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions increases activity |
EXP |
[pirinixic acid results in increased activity of PPARA protein] promotes the reaction [SLC22A21 protein results in increased uptake of Carnitine]; PPARA protein promotes the reaction [Carnitine results in decreased susceptibility to Gentamicins] Carnitine results in increased activity of PPARA protein |
CTD |
PMID:19491382 PMID:19735737 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression multiple interactions |
EXP |
Carnitine results in increased expression of PPARG protein Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of PPARG protein] |
CTD |
PMID:30256492 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgis |
prostaglandin I2 synthase |
increases expression increases response to substance multiple interactions |
EXP |
Carnitine results in increased expression of PTGIS mRNA PTGIS protein results in increased susceptibility to Carnitine [Carnitine results in increased expression of PTGIS mRNA] which results in increased chemical synthesis of 6-Ketoprostaglandin F1 alpha |
CTD |
PMID:19491382 |
|
NCBI chr 3:155,928,564...155,964,228
Ensembl chr 3:155,916,412...155,965,451
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in increased expression of RELA protein] |
CTD |
PMID:33965443 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc22a4 |
solute carrier family 22 member 4 |
increases uptake |
ISO |
SLC22A4 protein results in increased uptake of Carnitine |
CTD |
PMID:21256917 |
|
NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
multiple interactions decreases expression increases transport increases uptake increases expression affects uptake affects binding |
ISO EXP |
[Doxorubicin co-treated with Carnitine] results in increased expression of SLC22A5 mRNA; Amiodarone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Atorvastatin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Betaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; Choline inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Clozapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; grepafloxacin affects the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ipratropium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Lidocaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Nifedipine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Olanzapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine analog]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Propranolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Quetiapine Fumarate inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Spironolactone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; talinolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; ziprasidone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] Carnitine results in decreased expression of SLC22A5 mRNA; Carnitine results in decreased expression of SLC22A5 protein 1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [SLC22A5 protein results in increased uptake of Tetraethylammonium]; Dithioerythritol inhibits the reaction [Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Tetraethylammonium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] Carnitine deficiency results in increased expression of SLC22A5 mRNA SLC22A5 protein results in increased uptake of Carnitine; SLC22A5 protein results in increased uptake of Carnitine analog SLC22A5 protein affects the uptake of Carnitine Carnitine binds to SLC22A5 protein |
CTD |
PMID:12644265 PMID:15486076 PMID:16283381 PMID:16928358 PMID:18762717 PMID:18981167 PMID:19041296 PMID:19539806 PMID:19735737 PMID:20303936 PMID:20470772 PMID:21256917 PMID:21641380 PMID:22701146 PMID:30465787 PMID:31437515 More...
|
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
increases transport |
ISO |
SLC22A8 protein results in increased transport of Carnitine |
CTD |
PMID:15100168 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Slc25a20 |
solute carrier family 25 member 20 |
multiple interactions increases transport |
EXP |
Ampicillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Carnitine inhibits the reaction [Hydrogen Peroxide results in decreased activity of SLC25A20 protein]; Cefazolin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cefonicid inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cephalothin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Piperacillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine] |
CTD |
PMID:18452908 PMID:23402788 |
|
NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
increases expression multiple interactions |
EXP |
Carnitine results in increased expression of SLC2A4 protein Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of SLC2A4 protein] |
CTD |
PMID:30256492 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of SNAI1 protein] |
CTD |
PMID:28973641 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Stavudine results in increased expression of SREBF1 mRNA] |
CTD |
PMID:18299183 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
EXP |
Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR protein] |
CTD |
PMID:33965443 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TGFB1 mRNA]]; Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of TGFB1 mRNA]; Carnitine inhibits the reaction [sunitinib results in increased expression of TGFB1 mRNA] |
CTD |
PMID:26562095 PMID:26581635 PMID:28973641 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [sunitinib results in increased expression of TIMP1 mRNA] |
CTD |
PMID:26581635 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
EXP |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of TJP1 protein] |
CTD |
PMID:28973641 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions decreases expression |
EXP |
Carnitine deficiency results in increased expression of TNF mRNA [Carboplatin co-treated with Carnitine deficiency] results in increased expression of TNF protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased expression of TNF mRNA]; Carnitine inhibits the reaction [carbendazim results in increased expression of TNF protein]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF mRNA]]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF protein]] Carnitine results in decreased expression of TNF protein |
CTD |
PMID:18597074 PMID:18629605 PMID:18852009 PMID:26562095 PMID:33965443 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vim |
vimentin |
multiple interactions |
EXP |
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of VIM protein] |
CTD |
PMID:28973641 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
ISO EXP |
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding competes with [Epibatidine binds to Chrna2 protein] |
CTD RGD |
PMID:9454827 PMID:15016836 |
RGD:2303194 |
NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601
|
|
G |
Chrna3 |
cholinergic receptor nicotinic alpha 3 subunit |
multiple interactions |
ISO EXP |
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding [Epibatidine binds to Chrna3 protein] |
CTD RGD |
PMID:9454827 PMID:15016836 |
RGD:2303194 |
NCBI chr 8:55,401,981...55,415,012
Ensembl chr 8:55,401,702...55,415,165
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
ISO EXP |
Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrna4 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrna4 protein] |
CTD RGD |
PMID:9454827 PMID:14645658 PMID:15016836 |
RGD:2303194 |
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
multiple interactions increases response to substance increases activity |
ISO |
Dimethylphenylpiperazinium Iodide inhibits the reaction [Bungarotoxins binds to CHRNA7 protein] CHRNA7 protein mutant form results in increased susceptibility to Dimethylphenylpiperazinium Iodide Dimethylphenylpiperazinium Iodide results in increased activity of CHRNA7 protein |
CTD |
PMID:10082212 PMID:10216184 |
|
NCBI chr 1:116,715,286...116,837,223
Ensembl chr 1:116,714,711...116,837,240
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO EXP |
Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrnb2 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrnb2 protein] |
CTD RGD |
PMID:14645658 PMID:15016836 |
RGD:2303194 |
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
ISO |
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein] |
CTD |
PMID:9454827 |
|
NCBI chr 8:55,418,379...55,436,967
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Tnf |
tumor necrosis factor |
increases activity |
EXP |
TNF results in increased activity of Dimethylphenylpiperazinium Iodide |
CTD |
PMID:15086448 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
1,2-Dipalmitoylphosphatidylcholine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of IL6 protein] |
CTD |
PMID:19041333 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Prnp |
prion protein |
multiple interactions affects folding |
ISO |
Copper affects the reaction [1,2-Dipalmitoylphosphatidylcholine affects the folding of PRNP protein modified form] |
CTD |
PMID:20936829 |
|
NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937
|
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine |
CTD |
PMID:29906468 |
|
NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
|
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of 1-palmitoyl-2-linoleoylphosphatidylcholine |
CTD |
PMID:29906468 |
|
NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
|
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions |
ISO |
[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of 1-oleoyl lysophosphatidylcholine |
CTD |
PMID:29515023 |
|
NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326
|
|
G |
Smad3 |
SMAD family member 3 |
decreases abundance |
ISO |
SMAD3 protein results in decreased abundance of 1-oleoyl lysophosphatidylcholine |
CTD |
PMID:23034213 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of AGTR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of ALOX5 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CCR2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Cd68 |
Cd68 molecule |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CD68 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Crp |
C-reactive protein |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CRP mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions increases phosphorylation |
EXP |
AG 1879 inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein]; resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein] |
CTD |
PMID:24079413 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1A mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1B mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Kcnab2 |
potassium voltage-gated channel subfamily A regulatory beta subunit 2 |
multiple interactions |
EXP |
[KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine |
CTD |
PMID:21296056 |
|
NCBI chr 5:162,899,511...162,988,057
Ensembl chr 5:162,901,896...162,988,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
EXP |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:24079413 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP |
resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:24079413 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of OLR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Ptafr |
platelet-activating factor receptor |
affects binding multiple interactions |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine binds to PTAFR protein 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein] |
CTD |
PMID:16386258 |
|
NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Sele |
selectin E |
increases expression increases secretion |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of SELE mRNA 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of SELE protein |
CTD |
PMID:16386258 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions increases phosphorylation |
EXP |
resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of SRC protein] |
CTD |
PMID:24079413 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Timp4 |
TIMP metallopeptidase inhibitor 4 |
increases expression |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TIMP4 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:148,306,021...148,312,558
Ensembl chr 4:148,304,490...148,312,558
|
|
G |
Tnf |
tumor necrosis factor |
increases expression increases secretion |
ISO |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TNF mRNA 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of TNF protein |
CTD |
PMID:16386258 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Lipg |
lipase G, endothelial type |
increases hydrolysis |
ISO |
LIPG protein results in increased hydrolysis of 1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine |
CTD |
PMID:15953354 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of AGTR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase, 12S type |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of ALOX12 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions increases expression |
ISO |
[sodium arsenite co-treated with Platelet Activating Factor co-treated with Arachidonic Acid] results in increased phosphorylation of and results in increased activity of ALOX5 protein; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Calcimycin results in increased abundance of Platelet Activating Factor] Platelet Activating Factor results in increased expression of ALOX5 mRNA |
CTD |
PMID:8387780 PMID:10779545 PMID:16386258 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases secretion |
ISO |
Foropafant inhibits the reaction [Platelet Activating Factor results in increased secretion of CCL2 protein] |
CTD |
PMID:15149885 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of CCR2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Crp |
C-reactive protein |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of CRP mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of CX3CR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions increases abundance |
EXP |
Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]; EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18205269 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions |
EXP |
EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18205269 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of EGR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein; IMMLG5521 inhibits the reaction [[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein] |
CTD |
PMID:23850278 |
|
NCBI chr12:26,701,191...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of IL1A mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression increases secretion multiple interactions |
ISO |
Platelet Activating Factor results in increased expression of IL1B mRNA Platelet Activating Factor results in increased secretion of IL1B protein [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL1B protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein] |
CTD |
PMID:16386258 PMID:32830409 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases secretion |
ISO |
[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL6 protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein] |
CTD |
PMID:32830409 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions increases expression |
ISO |
Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]; Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein] |
CTD |
PMID:9762784 PMID:11116075 |
|
NCBI chr 1:182,659,047...182,709,495
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Ltb4r |
leukotriene B4 receptor |
affects response to substance |
ISO |
LTB4R1 protein affects the susceptibility to Platelet Activating Factor |
CTD |
PMID:10934231 |
|
NCBI chr15:29,263,126...29,265,716
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of MMP13 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
increases expression multiple interactions |
ISO |
Platelet Activating Factor results in increased expression of MYD88 protein PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein] |
CTD |
PMID:32830409 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
multiple interactions |
ISO |
NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor] |
CTD |
PMID:18164358 |
|
NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions increases degradation |
ISO |
Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Genistein inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; herbimycin inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein] |
CTD |
PMID:10921504 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of OLR1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Pla2g7 |
phospholipase A2 group VII |
multiple interactions increases expression |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Platelet Activating Factor] results in increased expression of PLA2G7 mRNA; bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PLA2G7 mRNA] |
CTD |
PMID:21432021 |
|
NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression |
ISO |
Platelet Activating Factor results in decreased expression of PPARA mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ptafr |
platelet-activating factor receptor |
multiple interactions increases expression increases phosphorylation affects binding |
ISO EXP |
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50730 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50739 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; CMI 392 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; MK 287 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; zileuton inhibits the reaction [Platelet Activating Factor binds to PTAFR protein] Platelet Activating Factor results in increased expression of PTAFR mRNA Platelet Activating Factor results in increased phosphorylation of PTAFR protein bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]; Carbon Tetrachloride promotes the reaction [Platelet Activating Factor binds to PTAFR protein]; RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein]; TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA] |
CTD |
PMID:9065783 PMID:10447766 PMID:11297424 PMID:11529688 PMID:16386258 PMID:18205269 More...
|
|
NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of PTGS1 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of PTGS2 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pvt1 |
Pvt1 oncogene |
increases expression multiple interactions |
ISO |
Platelet Activating Factor results in increased expression of PVT1 mRNA [Platelet Activating Factor co-treated with PVT1 mRNA] affects the expression of MIR149 mRNA; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein] |
CTD |
PMID:32830409 |
|
NCBI chr 7:93,656,249...93,879,938
|
|
G |
Rgs4 |
regulator of G-protein signaling 4 |
multiple interactions |
EXP |
RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein] |
CTD |
PMID:11297424 |
|
NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068
|
|
G |
Sele |
selectin E |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of SELE mRNA |
CTD |
PMID:16386258 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Sell |
selectin L |
multiple interactions increases secretion |
ISO |
Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein] |
CTD |
PMID:9762784 |
|
NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456
|
|
G |
Selp |
selectin P |
multiple interactions increases expression |
ISO |
Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of SELP protein] |
CTD |
PMID:11116075 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Timp4 |
TIMP metallopeptidase inhibitor 4 |
increases expression |
ISO |
Platelet Activating Factor results in increased expression of TIMP4 mRNA |
CTD |
PMID:16386258 |
|
NCBI chr 4:148,306,021...148,312,558
Ensembl chr 4:148,304,490...148,312,558
|
|
G |
Tnf |
tumor necrosis factor |
increases secretion multiple interactions increases expression |
ISO EXP |
Platelet Activating Factor results in increased secretion of TNF protein [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of TNF protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein] TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA] Platelet Activating Factor results in increased expression of TNF mRNA Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA] |
CTD |
PMID:9065783 PMID:10921504 PMID:16386258 PMID:32830409 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP |
platelet-activating factor increases expression of Tnf protein in portal stenosis rat plasma |
RGD |
PMID:10452877 |
RGD:38508900 |
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of 3-dehydrocarnitine Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 3-dehydrocarnitine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
|
G |
Bbox1 |
gamma-butyrobetaine hydroxylase 1 |
multiple interactions |
ISO |
[BBOX1 protein co-treated with Ketoglutaric Acids] results in increased metabolism of gamma-butyrobetaine |
CTD |
PMID:21439360 |
|
NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of gamma-butyrobetaine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
|
G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
affects binding |
IDA |
4-DAMP methiodide inhibits response to acetylcholine in rat aortic rings |
RGD |
PMID:8075871 |
RGD:2303390 |
NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
Ambenonium Chloride results in decreased activity of ACHE protein |
CTD |
PMID:33844597 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
App |
amyloid beta precursor protein |
affects cleavage |
EXP |
Ambenonium Chloride affects the cleavage of APP protein |
CTD |
PMID:11099780 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
|
G |
Aacs |
acetoacetyl-CoA synthetase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of AACS mRNA |
CTD |
PMID:31199489 |
|
NCBI chr12:31,113,098...31,156,411
Ensembl chr12:31,113,098...31,160,954
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ABCA1 mRNA |
CTD |
PMID:26919959 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abca12 |
ATP binding cassette subfamily A member 12 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ABCA12 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr 9:72,822,661...72,995,748
Ensembl chr 9:72,823,350...72,996,049
|
|
G |
Abca6 |
ATP binding cassette subfamily A member 6 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ABCA6 mRNA |
CTD |
PMID:20713136 |
|
NCBI chr10:95,142,805...95,212,087
Ensembl chr10:95,142,966...95,211,530
|
|
G |
Acod1 |
aconitate decarboxylase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ACOD1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr15:79,871,819...79,881,101
Ensembl chr15:79,871,827...79,880,529
|
|
G |
Acp6 |
acid phosphatase 6, lysophosphatidic |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ACP6 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:184,711,975...184,733,067
Ensembl chr 2:184,711,619...184,733,017
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ACSL4 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427
|
|
G |
Ada |
adenosine deaminase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ADA mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Adh1 |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ADH1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Adora1 |
adenosine A1 receptor |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ADORA1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ADRA2A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of AGTR2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr X:112,119,673...112,124,060
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of AKR1B10 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Alb |
albumin |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ALB mRNA |
CTD |
PMID:31199489 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Apoa1 |
apolipoprotein A1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of APOA1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoa2 |
apolipoprotein A2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of APOA2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
|
|
G |
Apoc1 |
apolipoprotein C1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of APOC1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of AQP3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Areg |
amphiregulin |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of AREG mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Arg2 |
arginase 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ARG2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Art3 |
ADP-ribosyltransferase 3 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ART3 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr14:15,637,230...15,719,442
Ensembl chr14:15,637,237...15,665,407
|
|
G |
Atf4 |
activating transcription factor 4 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ATF4 mRNA |
CTD |
PMID:28236482 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atp5f1e |
ATP synthase F1 subunit epsilon |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ATP5E mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 3:163,259,072...163,261,974
Ensembl chr 3:163,260,476...163,261,450
|
|
G |
Atp5mg |
ATP synthase membrane subunit g |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ATP5L mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 8:45,226,750...45,233,582
Ensembl chr 8:45,225,686...45,233,559
|
|
G |
B3galt4 |
Beta-1,3-galactosyltransferase 4 |
affects response to substance |
ISO |
B3GALT4 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,936,089...4,937,664
Ensembl chr20:4,931,768...4,938,315
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of BAMBI mRNA |
CTD |
PMID:20146380 |
|
NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Bcl3 |
BCL3, transcription coactivator |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of BCL3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607
|
|
G |
Btc |
betacellulin |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of BTC mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:16,708,447...16,746,961
Ensembl chr14:16,707,982...16,747,049
|
|
G |
C1s |
complement C1s |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C1S2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:157,430,249...157,442,438
Ensembl chr 4:157,430,117...157,442,303
|
|
G |
C3 |
complement C3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
Benzalkonium Compounds analog results in increased cleavage of CASP3 protein benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Benzalkonium Compounds analog results in increased cleavage of CASP3 protein] |
CTD |
PMID:31982400 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CASP8 mRNA |
CTD |
PMID:28236482 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCL11 protein |
CTD |
PMID:30517752 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression increases secretion |
ISO |
Benzalkonium Compounds results in increased expression of CCL2 mRNA; Benzalkonium Compounds results in increased expression of CCL2 protein Benzalkonium Compounds results in increased secretion of CCL2 protein |
CTD |
PMID:30171875 PMID:30517752 PMID:31707104 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCL20 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl24 |
C-C motif chemokine ligand 24 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CCL24 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr12:21,100,835...21,104,832
Ensembl chr12:21,100,835...21,104,893
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of CCL3 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL3 protein |
CTD |
PMID:30517752 PMID:31158415 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression multiple interactions increases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CCL4 mRNA; Benzalkonium Compounds results in decreased expression of CCL4 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL4 protein Benzalkonium Compounds results in increased expression of CCL4 protein |
CTD |
PMID:18353026 PMID:20713136 PMID:30517752 PMID:31158415 |
|
NCBI chr10:68,466,469...68,467,941
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCL5 protein |
CTD |
PMID:30517752 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCL7 mRNA; Benzalkonium Compounds results in increased expression of CCL7 protein |
CTD |
PMID:30171875 PMID:30517752 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CCN2 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccn3 |
cellular communication network factor 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCN3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:86,094,000...86,101,022
Ensembl chr 7:86,094,000...86,101,019
|
|
G |
Ccr4 |
C-C motif chemokine receptor 4 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CCR4 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 8:114,176,256...114,182,155
Ensembl chr 8:114,176,974...114,178,056
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCR5 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260
|
|
G |
Cd177 |
CD177 molecule |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD177 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:80,340,034...80,360,599
Ensembl chr 1:80,340,034...80,360,621
|
|
G |
Cd274 |
CD274 molecule |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD274 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:227,116,627...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cd300c2 |
CD300C molecule 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CD300C2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr10:100,253,312...100,258,553
Ensembl chr10:100,253,624...100,258,323
|
|
G |
Cfap61 |
cilia and flagella associated protein 61 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CFAP61 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 3:133,354,400...133,633,310
Ensembl chr 3:133,354,197...133,633,320
|
|
G |
Cfd |
complement factor D |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CFD mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CHIL1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CHRNB4 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 8:55,418,379...55,436,967
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Clcf1 |
cardiotrophin-like cytokine factor 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CLCF1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605
|
|
G |
Cnfn |
cornifelin |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CNFN mRNA; Benzalkonium Compounds results in increased expression of CNFN protein |
CTD |
PMID:25377654 |
|
NCBI chr 1:80,949,699...80,953,747
Ensembl chr 1:80,951,600...80,953,747
|
|
G |
Csf1 |
colony stimulating factor 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CSF1 protein |
CTD |
PMID:30517752 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csf2 |
colony stimulating factor 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CSF2 protein |
CTD |
PMID:30517752 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csf3 |
colony stimulating factor 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CSF3 protein |
CTD |
PMID:30517752 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Ctps1 |
CTP synthase 1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CTPS mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of CXCL10 mRNA; Benzalkonium Compounds results in increased expression of CXCL10 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL10 protein |
CTD |
PMID:23445166 PMID:30517752 PMID:31158415 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of CXCL2 mRNA; Benzalkonium Compounds results in increased expression of CXCL2 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL2 protein |
CTD |
PMID:30171875 PMID:30517752 PMID:31158415 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions increases expression |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL3 mRNA Benzalkonium Compounds results in increased expression of CXCL1 protein; Benzalkonium Compounds results in increased expression of CXCL3 mRNA |
CTD |
PMID:30171875 PMID:30517752 |
|
NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcr1 |
C-X-C motif chemokine receptor 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CXCR1 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 9:75,768,124...75,771,122
Ensembl chr 9:75,766,770...75,771,084
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CXCR4 mRNA |
CTD |
PMID:20713136 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases expression increases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CYP1A1 mRNA Benzalkonium Compounds results in increased expression of CYP1A1 mRNA |
CTD |
PMID:20713136 PMID:30806763 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:20713136 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CYP51 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of DHCR24 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:121,344,637...121,368,853
Ensembl chr 5:121,344,575...121,371,137
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
decreases activity increases expression |
ISO |
Benzalkonium Compounds results in decreased activity of DHCR7 protein Benzalkonium Compounds results in increased expression of DHCR7 mRNA |
CTD |
PMID:26919959 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
decreases activity |
ISO |
Benzalkonium Compounds results in decreased activity of DIO1 protein |
CTD |
PMID:30561685 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
decreases activity |
ISO |
Benzalkonium Compounds results in decreased activity of DIO2 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
decreases activity |
ISO |
Benzalkonium Compounds results in decreased activity of DIO3 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of DLK1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of DUSP1 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr10:16,680,489...16,683,276
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of EBP mRNA |
CTD |
PMID:26919959 |
|
NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826
|
|
G |
Egf |
epidermal growth factor |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of EGF mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of EGR1 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Elf3 |
E74 like ETS transcription factor 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ELF3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481
|
|
G |
Elovl1 |
ELOVL fatty acid elongase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ELOVL1 mRNA |
CTD |
PMID:29155129 |
|
NCBI chr 5:131,961,478...131,965,961
Ensembl chr 5:131,961,322...131,965,958
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ELOVL6 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186
|
|
G |
Endou |
endonuclease, poly(U)-specific |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ENDOU mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:128,845,862...128,866,542
Ensembl chr 7:128,844,862...128,866,596
|
|
G |
Eno1 |
enolase 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ENO1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Etnk1 |
ethanolamine kinase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ETNK1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:176,126,056...176,170,325
Ensembl chr 4:176,126,180...176,193,770
|
|
G |
Exo1 |
exonuclease 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of EXO1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654
|
|
G |
Ezr |
ezrin |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of EZR mRNA; Benzalkonium Compounds results in increased expression of EZR protein |
CTD |
PMID:29893927 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
Fam83a |
family with sequence similarity 83, member A |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of FAM83A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:89,522,826...89,547,284
Ensembl chr 7:89,522,826...89,547,388
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
affects response to substance |
ISO |
FGF2 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27206134 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgr |
FGR proto-oncogene, Src family tyrosine kinase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of FGR mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:145,189,814...145,219,571
Ensembl chr 5:145,189,841...145,217,326
|
|
G |
Flg |
filaggrin |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of FLG mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:178,888,688...178,912,731
|
|
G |
Foxc1 |
forkhead box C1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXC1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:32,631,379...32,635,361
Ensembl chr17:32,633,142...32,634,803
|
|
G |
Foxn1 |
forkhead box N1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXN1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr10:63,251,400...63,273,710
Ensembl chr10:63,251,400...63,273,710
|
|
G |
Foxp3 |
forkhead box P3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXP3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838
|
|
G |
Gata3 |
GATA binding protein 3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GATA3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of GCLC mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of GCLM mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of GPX2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HBEGF mRNA |
CTD |
PMID:30171875 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hck |
HCK proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HCK mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:141,571,587...141,614,696
Ensembl chr 3:141,571,587...141,614,693
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HGF mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HIF1A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HMGCR mRNA |
CTD |
PMID:26919959 PMID:31199489 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HMGCS2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Hoxa7 |
homeobox A7 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of HOXA7 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:81,315,730...81,317,629
Ensembl chr 4:81,314,625...81,317,659
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HSD17B7 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of HSPA5 mRNA |
CTD |
PMID:28236482 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ICAM1 mRNA; Benzalkonium Compounds results in increased expression of ICAM1 protein |
CTD |
PMID:21742781 PMID:30806763 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IDI1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357
|
|
G |
Ifng |
interferon gamma |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IFNG protein |
CTD |
PMID:30517752 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression |
ISO |
Benzalkonium Compounds results in increased expression of and results in decreased secretion of IL10 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL10 protein Benzalkonium Compounds results in increased expression of IL10 protein |
CTD |
PMID:29953848 PMID:30517752 PMID:31158415 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il13ra2 |
interleukin 13 receptor subunit alpha 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL13RA2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr X:111,002,590...111,074,053
Ensembl chr X:111,002,592...111,072,381
|
|
G |
Il15 |
interleukin 15 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL15 protein |
CTD |
PMID:30517752 |
|
NCBI chr19:25,640,013...25,706,818
Ensembl chr19:25,640,251...25,706,820
|
|
G |
Il17f |
interleukin 17F |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL17F mRNA |
CTD |
PMID:23445166 |
|
NCBI chr 9:23,190,094...23,201,482
Ensembl chr 9:23,190,100...23,201,482
|
|
G |
Il18 |
interleukin 18 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL18 protein Benzalkonium Compounds results in increased expression of IL18 mRNA |
CTD |
PMID:30517752 PMID:30806763 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1a |
interleukin 1 alpha |
increases secretion multiple interactions increases expression |
ISO |
Benzalkonium Compounds results in increased secretion of IL1A protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1A protein Benzalkonium Compounds results in increased expression of IL1A protein Benzalkonium Compounds results in increased expression of IL1A mRNA; Benzalkonium Compounds results in increased expression of IL1A protein |
CTD |
PMID:8006454 PMID:12781210 PMID:25290854 PMID:30240708 PMID:30517752 PMID:31158415 More...
|
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of IL1B protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1B protein |
CTD |
PMID:29953848 PMID:30517752 PMID:31158415 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1f10 |
interleukin 1 family member 10 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IL1F10 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:7,072,511...7,075,439
Ensembl chr 3:7,072,511...7,075,439
|
|
G |
Il23a |
interleukin 23 subunit alpha |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL23A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il27 |
interleukin 27 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL27 protein |
CTD |
PMID:30517752 |
|
NCBI chr 1:181,173,108...181,178,720
Ensembl chr 1:181,173,372...181,178,582
|
|
G |
Il3 |
interleukin 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL3 protein |
CTD |
PMID:30517752 |
|
NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066
|
|
G |
Il31 |
interleukin 31 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL31 protein |
CTD |
PMID:30517752 |
|
NCBI chr12:33,095,108...33,105,026
Ensembl chr12:33,092,097...33,105,037
|
|
G |
Il31ra |
interleukin 31 receptor A |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of IL31RA mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:44,118,748...44,189,943
Ensembl chr 2:44,122,624...44,183,767
|
|
G |
Il34 |
interleukin 34 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of IL34 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr19:38,714,990...38,782,749
Ensembl chr19:38,714,991...38,764,000
|
|
G |
Il36a |
interleukin 36, alpha |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL36A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:6,996,851...7,001,400
Ensembl chr 3:6,996,851...7,001,400
|
|
G |
Il36b |
interleukin 36, beta |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL36B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:7,024,862...7,122,489
Ensembl chr 3:7,021,973...7,031,619
|
|
G |
Il36g |
interleukin 36, gamma |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL36G mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:6,948,323...6,954,485
Ensembl chr 3:6,948,297...6,954,480
|
|
G |
Il4 |
interleukin 4 |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of IL4 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL4 protein |
CTD |
PMID:30517752 PMID:31158415 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL5 protein |
CTD |
PMID:30517752 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
increases secretion multiple interactions affects response to substance increases expression |
ISO |
Benzalkonium Compounds results in increased secretion of IL6 protein [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ADRA2A mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of AGTR2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C1S2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD177 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD274 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CTPS mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL5 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXC1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXN1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXP3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GATA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GSDMA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HCK mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HGF mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IGHA mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IL1F10 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRT2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP14 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP16-3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-5 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-9B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of LTB mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP25 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP9 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MRGPRA2B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MSX2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MYLK3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of NRG2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PDCD1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PROKR2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PTX3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG3G mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of RYR1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SAA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SERPINB13 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SIGLECE mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SOX21 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SRMS mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ST14 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TFAP2B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF13C mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF26 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFSF8 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TSLP mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of VTCN1 mRNA; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL6 protein Benzalkonium Compounds results in increased expression of IL6 mRNA; Benzalkonium Compounds results in increased expression of IL6 protein Benzalkonium Compounds results in increased expression of and results in increased secretion of IL6 protein |
CTD |
PMID:17763283 PMID:28214551 PMID:29953848 PMID:30171875 PMID:30517752 PMID:31158415 PMID:31707104 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il6r |
interleukin 6 receptor |
multiple interactions increases response to substance |
ISO |
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL10 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL4 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL3 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL4 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL10 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL2 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1A protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1B protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL22 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL6 protein |
CTD |
PMID:31158415 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Il7r |
interleukin 7 receptor |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL7R mRNA |
CTD |
PMID:20713136 |
|
NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757
|
|
G |
Inhba |
inhibin subunit beta A |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of INHBA mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982
|
|
G |
Insig1 |
insulin induced gene 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of INSIG1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Isl1 |
ISL LIM homeobox 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ISL1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:48,079,412...48,090,704
Ensembl chr 2:48,080,522...48,095,584
|
|
G |
Iyd |
iodotyrosine deiodinase |
multiple interactions |
ISO |
Benzalkonium Compounds inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Benzalkonium Compounds results in decreased activity of KCNH2 protein |
CTD |
PMID:24052561 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kdm8 |
lysine demethylase 8 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of KDM8 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:180,013,969...180,028,829
Ensembl chr 1:180,020,656...180,028,841
|
|
G |
Klk8 |
kallikrein related-peptidase 8 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of KLK8 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:94,251,803...94,258,646
Ensembl chr 1:94,251,803...94,258,646
|
|
G |
Krt2 |
keratin 2 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRT2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:132,941,275...132,947,963
Ensembl chr 7:132,940,862...132,947,963
|
|
G |
Krtap14 |
keratin associated protein 14 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP14 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr11:28,126,660...28,127,502
Ensembl chr11:28,126,660...28,127,502
|
|
G |
Lce3e |
late cornified envelope 3E |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of LCE3C mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:178,579,162...178,579,458
Ensembl chr 2:178,579,162...178,579,458
|
|
G |
Ldha |
lactate dehydrogenase A |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of LDHA mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of LDLR mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of LIF protein |
CTD |
PMID:30517752 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
LOC102551406 |
keratin-associated protein 20-2-like |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr11:28,412,307...28,412,508
Ensembl chr11:28,481,578...28,481,748
|
|
G |
LOC102552326 |
late cornified envelope protein 5A-like |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of LCE1M mRNA |
CTD |
PMID:30171875 |
|
Ensembl chr 2:178,275,020...178,275,469
|
|
G |
Loxl1 |
lysyl oxidase-like 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of LOXL1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 8:58,692,592...58,716,356
Ensembl chr 8:58,692,593...58,716,356
|
|
G |
Lst1 |
leukocyte specific transcript 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of LST1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr20:3,634,680...3,639,731
Ensembl chr20:3,634,749...3,637,997
|
|
G |
Ltb |
lymphotoxin beta |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of LTB mRNA |
CTD |
PMID:30171875 |
|
NCBI chr20:3,627,536...3,629,381
Ensembl chr20:3,627,537...3,629,381
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
increases phosphorylation |
ISO |
Benzalkonium Compounds results in increased phosphorylation of MAPK14 protein |
CTD |
PMID:15737199 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mesp2 |
mesoderm posterior bHLH transcription factor 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of MESP2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:133,756,601...133,759,207
Ensembl chr 1:133,756,601...133,759,198
|
|
G |
Mif |
macrophage migration inhibitory factor |
increases secretion |
ISO |
Benzalkonium Compounds results in increased secretion of MIF protein |
CTD |
PMID:31707104 |
|
NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of MMP10 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of MMP12 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611
|
|
G |
Mmp25 |
matrix metallopeptidase 25 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP25 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr10:12,661,297...12,676,119
Ensembl chr10:12,661,208...12,675,871
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP9 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Msmo1 |
methylsterol monooxygenase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of MSMO1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016
|
|
G |
Msx2 |
msh homeobox 2 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MSX2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:11,097,214...11,102,879
Ensembl chr17:11,097,103...11,102,879
|
|
G |
Mt2A |
metallothionein 2A |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of MT2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Mylk3 |
myosin light chain kinase 3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MYLK3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr19:21,685,085...21,743,587
Ensembl chr19:21,691,929...21,742,954
|
|
G |
Ndufa4 |
Ndufa4, mitochondrial complex associated |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of NDUFA4 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:40,002,216...40,009,384
Ensembl chr 4:40,002,216...40,023,920
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of NR4A2 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877
|
|
G |
Nrg2 |
neuregulin 2 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of NRG2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr18:27,619,635...27,798,505
Ensembl chr18:27,619,661...27,798,505
|
|
G |
Ntrk3 |
neurotrophic receptor tyrosine kinase 3 |
affects response to substance |
ISO |
NTRK3 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27206134 |
|
NCBI chr 1:132,116,472...132,503,849
Ensembl chr 1:132,132,849...132,503,286
|
|
G |
Ocln |
occludin |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of OCLN protein |
CTD |
PMID:29514330 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ODC1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Odf3l2 |
outer dense fiber of sperm tails 3-like 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ODF3L2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:10,049,472...10,065,626
Ensembl chr 7:10,059,589...10,065,125
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of OLR1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Orm1 |
orosomucoid 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ORM1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
Benzalkonium Compounds analog results in increased cleavage of PARP1 protein benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Benzalkonium Compounds analog results in increased cleavage of PARP1 protein] |
CTD |
PMID:31982400 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pbk |
PDZ binding kinase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PBK mRNA |
CTD |
PMID:30171875 |
|
NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014
|
|
G |
Pcsk9 |
proprotein convertase subtilisin/kexin type 9 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of PCSK9 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688
|
|
G |
Pdcd1 |
programmed cell death 1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PDCD1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:94,418,786...94,431,945
Ensembl chr 9:94,418,791...94,431,937
|
|
G |
Pfdn6 |
prefoldin subunit 6 |
affects response to substance |
ISO |
PFDN6 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,945,959...4,947,433
Ensembl chr20:4,945,959...4,947,433
|
|
G |
Pglyrp3 |
peptidoglycan recognition protein 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PGLYRP3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:177,479,693...177,490,867
Ensembl chr 2:177,477,407...177,490,736
|
|
G |
Pgp |
phosphoglycolate phosphatase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PGP mRNA |
CTD |
PMID:31199489 |
|
NCBI chr10:13,495,232...13,497,858
Ensembl chr10:13,494,291...13,497,858
|
|
G |
Pla2g5 |
phospholipase A2, group V |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of PLA2G5 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:151,041,339...151,109,433
Ensembl chr 5:151,041,340...151,062,658
|
|
G |
Plcxd3 |
phosphatidylinositol-specific phospholipase C, X domain containing 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PLCXD3 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:53,567,022...53,746,384
Ensembl chr 2:53,567,022...53,746,384
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of PNPLA2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805
|
|
G |
Polr1d |
RNA polymerase I and III subunit D |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of POLR1D mRNA |
CTD |
PMID:31199489 |
|
NCBI chr12:7,970,592...8,004,157
Ensembl chr12:7,970,595...8,005,624
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of PPARA mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PRKAA2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Prkag2 |
protein kinase AMP-activated non-catalytic subunit gamma 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PRKAG2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:10,010,574...10,252,152
Ensembl chr 4:10,010,890...10,252,142
|
|
G |
Prokr2 |
prokineticin receptor 2 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PROKR2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:119,624,738...119,639,442
Ensembl chr 3:119,627,601...119,635,718
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PTGS2 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptx3 |
pentraxin 3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PTX3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323
|
|
G |
Reg1a |
regenerating family member 1 alpha |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:110,892,451...110,895,115
Ensembl chr 4:110,892,453...110,895,570
|
|
G |
Reg3g |
regenerating family member 3 gamma |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG3G mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:110,922,805...110,927,803
Ensembl chr 4:110,924,168...110,926,723
|
|
G |
Rgl2 |
ral guanine nucleotide dissociation stimulator-like 2 |
affects response to substance |
ISO |
RGL2 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,948,495...4,956,774
Ensembl chr20:4,948,497...4,969,911
|
|
G |
Rps18 |
ribosomal protein S18 |
affects response to substance |
ISO |
RPS18 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,931,427...4,935,538
Ensembl chr10:101,204,500...101,205,146 Ensembl chr20:101,204,500...101,205,146
|
|
G |
RT1-DOa |
RT1 class II, locus DOa |
affects response to substance |
ISO |
HLA-DOA SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,753,587...4,756,590
Ensembl chr20:4,753,598...4,756,577
|
|
G |
RT1-DOb |
RT1 class II, locus DOb |
affects response to substance |
ISO |
HLA-DOB SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,619,599...4,625,627
Ensembl chr20:4,619,816...4,625,667
|
|
G |
RT1-Ha |
RT1 class II, locus Ha |
affects response to substance |
ISO |
HLA-DPA1 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,760,631...4,770,662
Ensembl chr20:4,760,118...4,770,244
|
|
G |
Ryr1 |
ryanodine receptor 1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of RYR1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:84,292,578...84,423,799
Ensembl chr 1:84,292,578...84,423,812
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression decreases expression |
ISO |
Benzalkonium Compounds results in increased expression of SCD mRNA Benzalkonium Compounds results in decreased expression of SCD1 mRNA |
CTD |
PMID:29155129 PMID:31199489 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Serpinb13 |
serpin family B member 13 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SERPINB13 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:23,118,584...23,150,760
Ensembl chr13:23,118,584...23,150,760
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SERPINE1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sesn2 |
sestrin 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of SESN2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Sfn |
stratifin |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SFN mRNA |
CTD |
PMID:30171875 |
|
Ensembl chr 5:145,826,201...145,831,314
|
|
G |
Sfrp4 |
secreted frizzled-related protein 4 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of SFRP4 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:45,278,867...45,330,806
Ensembl chr17:45,234,097...45,330,736
|
|
G |
Siglec8 |
sialic acid binding Ig-like lectin 8 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SIGLECE mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:94,092,737...94,103,134
Ensembl chr 1:94,093,395...94,103,034
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SLC16A1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SLC7A11 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Sox21 |
SRY-box transcription factor 21 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SOX21 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr15:95,292,272...95,295,316
Ensembl chr15:95,292,265...95,296,091
|
|
G |
Sprr1a |
small proline-rich protein 1A |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SPRR1A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:178,055,096...178,057,012
Ensembl chr 2:178,055,096...178,057,063
|
|
G |
Sprr1b |
small proline-rich protein 1B |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SPRR1B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:178,009,130...178,009,567
Ensembl chr 2:178,009,130...178,009,567
|
|
G |
Sprr2b |
small proline rich protein 2B |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SPRR2B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:177,852,824...177,853,096
Ensembl chr 2:177,852,824...177,853,096
|
|
G |
Sprr2f |
small proline rich protein 2F |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SPRR2F mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:177,989,974...177,990,204
Ensembl chr 2:177,989,974...177,990,204
|
|
G |
Sqle |
squalene epoxidase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SQLE mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SREBF2 mRNA |
CTD |
PMID:26919959 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Srms |
src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SRMS mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:168,318,511...168,324,915
Ensembl chr 3:168,318,512...168,324,915
|
|
G |
St14 |
ST14 transmembrane serine protease matriptase |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ST14 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 8:29,540,805...29,581,704
Ensembl chr 8:29,540,811...29,581,517
|
|
G |
Tapbp |
TAP binding protein |
affects response to substance |
ISO |
TAPBP SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,956,937...4,966,191
Ensembl chr20:4,956,937...4,966,181
|
|
G |
Tfap2b |
transcription factor AP-2 beta |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TFAP2B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:21,786,250...21,815,785
Ensembl chr 9:21,786,258...21,814,520
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TGFB1 protein |
CTD |
PMID:30517752 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgm3 |
transglutaminase 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TGM3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:117,228,661...117,264,078
Ensembl chr 3:117,228,661...117,264,075
|
|
G |
Tgm7 |
transglutaminase 7 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of TGM7 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:108,051,890...108,068,116
Ensembl chr 3:108,051,890...108,076,239
|
|
G |
Thbs1 |
thrombospondin 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of THBS1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:105,056,286...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Tlr1 |
toll-like receptor 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TLR1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:43,384,127...43,396,765
Ensembl chr14:43,384,932...43,397,125
|
|
G |
Tlr4 |
toll-like receptor 4 |
increases activity |
ISO |
Benzalkonium Compounds results in increased activity of TLR4 protein |
CTD |
PMID:29514330 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tmprss11b |
transmembrane serine protease 11B |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TMPRSS11B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:21,385,924...21,405,894
Ensembl chr14:21,383,862...21,408,817
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion increases expression |
ISO |
Benzalkonium Compounds results in decreased secretion of TNF protein Benzalkonium Compounds results in increased expression of TNF mRNA; Benzalkonium Compounds results in increased expression of TNF protein |
CTD |
PMID:29953848 PMID:30171875 PMID:30517752 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TNFAIP6 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Tnfrsf13c |
TNF receptor superfamily member 13C |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF13C mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:113,736,046...113,738,523
Ensembl chr 7:113,736,055...113,738,517
|
|
G |
Tnfrsf9 |
TNF receptor superfamily member 9 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TNFRSF9 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000
|
|
G |
Tnfsf8 |
TNF superfamily member 8 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFSF8 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:77,253,881...77,277,078
Ensembl chr 5:77,251,373...77,277,421
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of TP53 mRNA |
CTD |
PMID:28236482 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of TPI1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541
|
|
G |
Trem2 |
triggering receptor expressed on myeloid cells 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TREM2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:12,647,605...12,654,190
Ensembl chr 9:12,647,259...12,654,170
|
|
G |
Tslp |
thymic stromal lymphopoietin |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TSLP mRNA |
CTD |
PMID:30171875 |
|
NCBI chr18:24,447,409...24,454,244
Ensembl chr18:24,449,844...24,453,548
|
|
G |
Upk3b |
uroplakin 3B |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of UPK3B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr12:20,629,491...20,638,193
Ensembl chr12:20,631,525...20,637,724
|
|
G |
Uqcrq |
ubiquinol-cytochrome c reductase, complex III subunit VII |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of UQCRQ mRNA |
CTD |
PMID:31199489 |
|
NCBI chr10:37,585,864...37,589,328
Ensembl chr10:37,586,888...37,589,169
|
|
G |
Vegfd |
vascular endothelial growth factor D |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of VEGFD mRNA |
CTD |
PMID:20146380 |
|
NCBI chr X:30,073,122...30,108,413
Ensembl chr X:30,074,163...30,108,295
|
|
G |
Vtcn1 |
V-set domain containing T cell activation inhibitor 1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of VTCN1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:188,253,594...188,321,658
Ensembl chr 2:188,253,594...188,321,658
|
|
G |
Wdr46 |
WD repeat domain 46 |
affects response to substance |
ISO |
WDR46 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,937,845...4,945,796
Ensembl chr20:4,937,847...4,946,535
|
|
G |
Xbp1 |
X-box binding protein 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of XBP1 mRNA alternative form |
CTD |
PMID:28236482 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
G |
Xcl1 |
X-C motif chemokine ligand 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of XCL1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:77,248,865...77,252,308
Ensembl chr13:77,248,717...77,252,329
|
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Benzethonium results in decreased expression of CCL2 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
decreases expression |
ISO |
Benzethonium results in decreased expression of CCL3 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression |
ISO |
Benzethonium results in decreased expression of CCL4 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,466,469...68,467,941
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
decreases expression |
ISO |
Benzethonium results in decreased expression of CCL5 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Benzethonium co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
Benzethonium results in decreased expression of IL1B mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[Benzethonium co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6r |
interleukin 6 receptor |
decreases expression |
ISO |
Benzethonium results in decreased expression of IL6R protein modified form |
CTD |
PMID:20116850 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Kcna3 |
potassium voltage-gated channel subfamily A member 3 |
decreases activity multiple interactions |
ISO |
Benzethonium results in decreased activity of KCNA3 protein [Benzethonium results in decreased activity of KCNA3 protein] which results in decreased import of Thallium |
CTD |
PMID:21362439 |
|
NCBI chr 2:194,632,360...194,633,937
Ensembl chr 2:194,632,196...194,650,138
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
[Benzethonium results in decreased activity of KCNH2 protein] which results in decreased import of Thallium |
CTD |
PMID:21362439 PMID:23313619 PMID:24052561 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Benzethonium inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Benzethonium results in decreased expression of VEGFA protein |
CTD |
PMID:20116850 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Bretylium Tosylate inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Butylscopolammonium Bromide inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
affects binding increases uptake multiple interactions increases transport |
ISO EXP |
pivaloylcarnitine binds to SLC22A5 protein SLC22A5 protein results in increased uptake of pivaloylcarnitine Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine] |
CTD |
PMID:18762717 PMID:19539806 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
Chlormequat promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein] |
CTD |
PMID:25684042 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
decreases expression |
EXP |
Chlormequat results in decreased expression of BGLAP protein |
CTD |
PMID:28214531 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Chlormequat results in decreased expression of CYP11A1 protein |
CTD |
PMID:29447956 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
increases expression |
ISO |
Chlormequat results in increased expression of CYP7A1 protein |
CTD |
PMID:32194361 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Gh1 |
growth hormone 1 |
increases expression |
EXP |
Chlormequat results in increased expression of GH1 protein |
CTD |
PMID:31704167 PMID:32622971 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Ghr |
growth hormone receptor |
decreases expression |
EXP |
Chlormequat results in decreased expression of GHR mRNA |
CTD |
PMID:28214531 |
|
NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735
|
|
G |
Ghrh |
growth hormone releasing hormone |
increases expression |
EXP |
Chlormequat results in increased expression of GHRH protein |
CTD |
PMID:32622971 |
|
NCBI chr 3:145,992,762...146,012,528
Ensembl chr 3:145,992,763...146,011,889
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
increases expression |
EXP |
Chlormequat results in increased expression of GNRH1 protein |
CTD |
PMID:29447956 |
|
NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581 Ensembl chr15:41,972,905...41,973,581
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
decreases expression |
EXP |
Chlormequat results in decreased expression of HSD3B1 protein |
CTD |
PMID:29447956 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Igf1 |
insulin-like growth factor 1 |
affects expression increases expression |
EXP |
Chlormequat affects the expression of IGF1 protein Chlormequat results in increased expression of IGF1 protein |
CTD |
PMID:28214531 PMID:31704167 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Lhb |
luteinizing hormone subunit beta |
increases expression |
EXP |
Chlormequat results in increased expression of LHB protein |
CTD |
PMID:29447956 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression |
EXP |
Chlormequat results in decreased expression of STAR protein |
CTD |
PMID:29447956 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
affects expression |
EXP |
Chlormequat affects the expression of TNFSF11 mRNA |
CTD |
PMID:28214531 |
|
NCBI chr15:53,674,990...53,705,171
Ensembl chr15:53,673,877...53,705,445
|
|
|
G |
Crp |
C-reactive protein |
decreases expression |
ISO |
Colesevelam Hydrochloride results in decreased expression of CRP protein |
CTD |
PMID:16616026 |
|
NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions increases expression |
ISO |
Colesevelam Hydrochloride promotes the reaction [Simvastatin results in increased expression of HMGCR mRNA] Colesevelam Hydrochloride results in increased expression of HMGCR mRNA |
CTD |
PMID:22120639 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
Colesevelam Hydrochloride results in increased expression of LDLR mRNA |
CTD |
PMID:22120639 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
Echothiophate Iodide results in decreased activity of ACHE protein |
CTD |
PMID:16978018 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Echothiophate Iodide binds to ALB protein |
CTD |
PMID:15525694 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Bche |
butyrylcholinesterase |
decreases activity multiple interactions |
ISO |
Echothiophate Iodide results in decreased activity of BCHE protein Echothiophate Iodide inhibits the reaction [BCHE protein results in increased hydrolysis of Butyrylthiocholine] |
CTD |
PMID:7377577 PMID:16213467 PMID:17698511 PMID:21802514 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
decreases activity |
ISO |
Echothiophate Iodide results in decreased activity of NCEH1 protein |
CTD |
PMID:16978018 |
|
NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
ISO |
Ergothioneine inhibits the reaction [Cisplatin results in decreased activity of ACHE protein] |
CTD |
PMID:20932872 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:33580994 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein] |
CTD |
PMID:33580994 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased activity of CAT protein] |
CTD |
PMID:33580994 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein] |
CTD |
PMID:33580994 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein] |
CTD |
PMID:33580994 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein] |
CTD |
PMID:33580994 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of PIK3CA protein] |
CTD |
PMID:33580994 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein] |
CTD |
PMID:33580994 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein] |
CTD |
PMID:33580994 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ABCC4 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abi3bp |
ABI family member 3 binding protein |
increases expression |
EXP |
Betaine results in increased expression of ABI3BP mRNA |
CTD |
PMID:26391144 |
|
NCBI chr11:43,912,187...44,128,888
Ensembl chr11:43,913,043...44,128,929
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
EXP |
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in increased expression of ACACA mRNA |
CTD |
PMID:22648174 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ACACB mRNA |
CTD |
PMID:33549593 |
|
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Adgrg2 |
adhesion G protein-coupled receptor G2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ADGRG2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr X:34,297,402...34,422,590
Ensembl chr X:34,297,402...34,422,609
|
|
G |
Adss |
adenylosuccinate synthase |
decreases expression |
EXP |
Betaine results in decreased expression of ADSS mRNA |
CTD |
PMID:26391144 |
|
NCBI chr13:89,769,240...89,799,577
Ensembl chr13:89,769,244...89,799,604
|
|
G |
Ahcy |
adenosylhomocysteinase |
decreases expression |
ISO EXP |
Betaine results in decreased expression of AHCY mRNA |
CTD |
PMID:22945834 PMID:26391144 |
|
NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393
|
|
G |
Akip1 |
A-kinase interacting protein 1 |
increases expression |
EXP |
Betaine results in increased expression of AKIP1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:163,734,730...163,743,648
Ensembl chr 1:163,734,798...163,743,648
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
decreases expression |
EXP |
Betaine results in decreased expression of AKR1B1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1b7 |
aldo-keto reductase family 1, member B7 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of AKR1B7 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 4:63,053,560...63,100,934
Ensembl chr 4:63,076,800...63,089,502
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
ISO |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of ALDH2 protein |
CTD |
PMID:20118189 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
decreases expression |
EXP |
Betaine results in decreased expression of APEX1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Betaine inhibits the reaction [Azacitidine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [Azacitidine results in increased expression of and results in increased cleavage of APP protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in increased expression of and results in increased cleavage of APP protein] |
CTD |
PMID:19635394 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Atp7b |
ATPase copper transporting beta |
multiple interactions |
ISO |
ATP7B protein mutant form promotes the reaction [Betaine results in increased abundance of S-Adenosylmethionine]; Betaine inhibits the reaction [ATP7B protein mutant form results in increased abundance of Copper]; Betaine inhibits the reaction [ATP7B protein mutant form results in increased expression of TNF mRNA] |
CTD |
PMID:22945834 |
|
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Axin1 |
axin 1 |
multiple interactions |
ISO |
[Folic Acid co-treated with Vitamin B 12 co-treated with Betaine co-treated with Choline] results in increased methylation of AXIN1 gene |
CTD |
PMID:16868943 |
|
NCBI chr10:15,163,684...15,215,615
Ensembl chr10:15,163,684...15,215,615
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression |
EXP |
Betaine results in decreased expression of BAX protein |
CTD |
PMID:25080425 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
affects binding increases expression |
ISO EXP |
Betaine analog binds to BCL2 protein Betaine results in increased expression of BCL2 protein |
CTD |
PMID:25080425 PMID:25765238 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
increases expression |
EXP |
Betaine results in increased expression of BHLHE40 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
increases metabolic processing |
ISO |
BHMT protein results in increased metabolism of Betaine |
CTD |
PMID:18230605 |
|
NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742
|
|
G |
Brf1 |
BRF1, RNA polymerase III transcription initiation factor subunit |
multiple interactions |
ISO |
Betaine inhibits the reaction [Ethanol results in increased expression of BRF1 mRNA]; Betaine inhibits the reaction [Ethanol results in increased expression of BRF1 protein] |
CTD |
PMID:32418914 |
|
NCBI chr 6:132,034,380...132,081,296
Ensembl chr 6:132,037,272...132,081,278
|
|
G |
Cab39l |
calcium binding protein 39-like |
decreases expression |
EXP |
Betaine results in decreased expression of CAB39L mRNA |
CTD |
PMID:26391144 |
|
NCBI chr15:33,606,588...33,710,518
Ensembl chr15:33,606,694...33,743,545
|
|
G |
Casp1 |
caspase 1 |
increases expression |
EXP |
Betaine results in increased expression of CASP1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
Betaine inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein] |
CTD |
PMID:24632105 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
ISO EXP |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased activity of CAT protein Betaine inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein]; Betaine inhibits the reaction [Carbon Tetrachloride results in increased activity of CAT protein] |
CTD |
PMID:12893363 PMID:20118189 PMID:24632105 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccdc113 |
coiled-coil domain containing 113 |
increases expression |
EXP |
Betaine results in increased expression of CCDC113 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr19:9,497,000...9,516,917
Ensembl chr19:9,496,886...9,516,923
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in decreased expression of CCL2 mRNA |
CTD |
PMID:22648174 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
EXP |
Betaine results in increased expression of CCL5 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl6 |
C-C motif chemokine ligand 6 |
increases expression |
EXP |
Betaine results in increased expression of CCL6 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:68,381,179...68,385,811
Ensembl chr10:68,380,188...68,384,001
|
|
G |
Ccnb2 |
cyclin B2 |
decreases expression |
EXP |
Betaine results in decreased expression of CCNB2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
decreases expression |
EXP |
Betaine results in decreased expression of CD44 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cdc42ep2 |
CDC42 effector protein 2 |
decreases expression |
EXP |
Betaine results in decreased expression of CDC42EP2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:203,202,000...203,210,891
Ensembl chr 1:203,201,873...203,210,897
|
|
G |
Cdh13 |
cadherin 13 |
decreases expression |
EXP |
Betaine results in decreased expression of CDH13 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr19:46,349,562...47,387,462
Ensembl chr19:46,349,430...47,387,459
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CDK1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
EXP |
Betaine promotes the reaction [Diethylnitrosamine results in decreased expression of CDKN2A mRNA] |
CTD |
PMID:19642983 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Ces2c |
carboxylesterase 2C |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CES2C mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790
|
|
G |
Ces3a |
carboxylesterase 3a |
increases expression |
EXP |
Betaine results in increased expression of CES3 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr19:32,992,386...33,000,562
|
|
G |
Ckb |
creatine kinase B |
increases expression |
EXP |
Betaine results in increased expression of CKB mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Cks1b |
CDC28 protein kinase regulatory subunit 1B |
decreases expression |
EXP |
Betaine results in decreased expression of CKS1B mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 2:174,833,025...174,837,614
Ensembl chr 2:174,833,050...174,837,636
|
|
G |
Clcf1 |
cardiotrophin-like cytokine factor 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CLCF1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605
|
|
G |
Cotl1 |
coactosin-like F-actin binding protein 1 |
decreases expression |
EXP |
Betaine results in decreased expression of COTL1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr19:47,871,689...47,906,010
Ensembl chr19:47,871,694...47,911,689
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions decreases expression |
ISO |
Betaine inhibits the reaction [CPT1A protein mutant form results in decreased expression of DNMT1 mRNA] Betaine results in decreased expression of CPT1A mRNA |
CTD |
PMID:22945834 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cxcl16 |
C-X-C motif chemokine ligand 16 |
decreases expression |
EXP |
Betaine results in decreased expression of CXCL16 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP26A1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2B10 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2C55 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate] inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein] Betaine promotes the reaction [Ethanol results in increased expression of CYP2E1] |
CTD |
PMID:20118189 PMID:21352821 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cysltr1 |
cysteinyl leukotriene receptor 1 |
increases expression |
EXP |
Betaine results in increased expression of CYSLTR1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr X:71,661,415...71,690,158
Ensembl chr X:71,663,821...71,690,121
|
|
G |
Dapk1 |
death associated protein kinase 1 |
decreases expression |
EXP |
Betaine results in decreased expression of DAPK1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
|
|
G |
Depp1 |
DEPP1, autophagy regulator |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of DEPP1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
|
|
G |
Dlx2 |
distal-less homeobox 2 |
increases expression |
EXP |
Betaine results in increased expression of DLX2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:56,371,347...56,373,230
Ensembl chr 3:56,370,483...56,373,597
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions increases expression |
ISO |
Betaine inhibits the reaction [CPT1A protein mutant form results in decreased expression of DNMT1 mRNA] Betaine results in increased expression of DNMT1 mRNA |
CTD |
PMID:22945834 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
decreases expression |
ISO |
Betaine results in decreased expression of DNMT3B mRNA |
CTD |
PMID:22945834 |
|
NCBI chr 3:142,130,592...142,169,124
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
E2f8 |
E2F transcription factor 8 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of E2F8 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
|
|
G |
Ect2 |
epithelial cell transforming 2 |
decreases expression |
EXP |
Betaine results in decreased expression of ECT2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 2:109,975,813...110,037,911
Ensembl chr 2:109,975,813...110,037,911
|
|
G |
Eef2k |
eukaryotic elongation factor-2 kinase |
increases expression |
EXP |
Betaine results in increased expression of EEF2K mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:175,393,119...175,454,452
Ensembl chr 1:175,393,154...175,455,164
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of EGFR mRNA |
CTD |
PMID:33549593 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
increases expression multiple interactions |
EXP ISO |
Betaine results in increased expression of EGR1 mRNA [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of EGR1 mRNA |
CTD |
PMID:26391144 PMID:33549593 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Elf3 |
E74 like ETS transcription factor 3 |
decreases expression |
EXP |
Betaine results in decreased expression of ELF3 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481
|
|
G |
Emc9 |
ER membrane protein complex subunit 9 |
increases expression |
EXP |
Betaine results in increased expression of EMC9 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr15:29,071,881...29,076,098
Ensembl chr15:29,071,883...29,076,098
|
|
G |
Ephb6 |
Eph receptor B6 |
increases expression |
EXP |
Betaine results in increased expression of EPHB6 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:70,491,973...70,507,230
Ensembl chr 4:70,491,973...70,507,230
|
|
G |
Esco2 |
establishment of sister chromatid cohesion N-acetyltransferase 2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ESCO2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr15:40,034,566...40,052,295
Ensembl chr15:40,034,568...40,055,306
|
|
G |
F8 |
coagulation factor VIII |
multiple interactions increases secretion |
ISO |
Betaine affects the localization of and results in increased secretion of F8 protein; Betaine affects the localization of and results in increased secretion of F8 protein mutant form Betaine results in increased secretion of F8 protein; Betaine results in increased secretion of F8 protein mutant form |
CTD |
PMID:22973456 |
|
NCBI chr18:140,848...172,330
Ensembl chr18:140,955...171,857
|
|
G |
F9 |
coagulation factor IX |
increases secretion |
ISO |
Betaine results in increased secretion of F9 protein |
CTD |
PMID:22973456 |
|
NCBI chr X:138,352,334...138,396,835
Ensembl chr X:138,352,298...138,396,835
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of FABP5 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
EXP |
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid] affects the reaction [[Dietary Fats co-treated with Dietary Sucrose] affects the methylation of FASN promoter] |
CTD |
PMID:22648174 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Flrt3 |
fibronectin leucine rich transmembrane protein 3 |
increases expression |
EXP |
Betaine results in increased expression of FLRT3 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:127,994,491...128,008,137
Ensembl chr 3:127,994,226...128,007,841
|
|
G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
decreases expression |
EXP |
Betaine results in decreased expression of FXYD2 mRNA; Betaine results in decreased expression of FXYD2 mRNA alternative form |
CTD |
PMID:26391144 |
|
NCBI chr 8:45,712,887...45,720,032
Ensembl chr 8:45,712,903...45,720,203
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GADD45B mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of GADD45G mRNA |
CTD |
PMID:33549593 |
|
NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610
|
|
G |
Gal |
galanin and GMAP prepropeptide |
multiple interactions |
EXP |
Betaine inhibits the reaction [Isoproterenol results in decreased activity of GAL protein]; Betaine inhibits the reaction [Isoproterenol results in increased activity of GAL protein] |
CTD |
PMID:19294532 |
|
NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959
|
|
G |
Gck |
glucokinase |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of GCK mRNA |
CTD |
PMID:33549593 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gna14 |
G protein subunit alpha 14 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GNA14 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:213,714,993...213,900,083
Ensembl chr 1:213,716,020...213,897,423
|
|
G |
Gpcpd1 |
glycerophosphocholine phosphodiesterase 1 |
increases expression multiple interactions |
EXP ISO |
Betaine results in increased expression of GPCPD1 mRNA [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of GPCPD1 mRNA |
CTD |
PMID:26391144 PMID:33549593 |
|
NCBI chr 3:119,787,681...119,832,550
Ensembl chr 3:119,787,682...119,832,517
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GSTA5 mRNA; [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of GSTA5 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GSTM3 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 2:195,531,627...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
Betaine inhibits the reaction [Isoproterenol results in decreased activity of GUSB protein]; Betaine inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] |
CTD |
PMID:19294532 |
|
NCBI chr12:26,701,191...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
H2az1 |
H2A.Z variant histone 1 |
decreases expression |
EXP |
Betaine results in decreased expression of H2AZ1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 2:226,355,769...226,357,878
Ensembl chr 2:226,355,708...226,358,485
|
|
G |
Hip1 |
huntingtin interacting protein 1 |
decreases expression |
EXP |
Betaine results in decreased expression of HIP1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr12:21,133,319...21,267,796
Ensembl chr12:21,133,406...21,267,725
|
|
G |
Hmgb2 |
high mobility group box 2 |
decreases expression |
EXP |
Betaine results in decreased expression of HMGB2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
decreases expression |
ISO |
Betaine results in decreased expression of HSPA5 mRNA |
CTD |
PMID:22945834 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
increases expression |
EXP |
Betaine results in increased expression of ID2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of Betaine Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Betaine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of IRS2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Irx4 |
iroquois homeobox 4 |
decreases expression |
EXP |
Betaine results in decreased expression of IRX4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:30,030,561...30,039,549
Ensembl chr 1:30,030,561...30,039,549
|
|
G |
Itga8 |
integrin subunit alpha 8 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ITGA8 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr17:75,304,004...75,501,510
Ensembl chr17:75,304,008...75,501,510
|
|
G |
Itgb4 |
integrin subunit beta 4 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ITGB4 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr10:101,206,657...101,243,012
Ensembl chr10:101,206,665...101,243,012
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Betaine results in increased expression of JUN mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Khdrbs3 |
KH RNA binding domain containing, signal transduction associated 3 |
decreases expression |
EXP |
Betaine results in decreased expression of KHDRBS3 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 7:100,837,707...100,995,644
Ensembl chr 7:100,837,934...100,988,460
|
|
G |
Kif1b |
kinesin family member 1B |
increases expression |
EXP |
Betaine results in increased expression of KIF1B mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:159,607,697...159,742,778
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Kif22 |
kinesin family member 22 |
decreases expression |
EXP |
Betaine results in decreased expression of KIF22 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:181,635,347...181,650,351
Ensembl chr 1:181,635,183...181,650,401
|
|
G |
Klf10 |
Kruppel-like factor 10 |
increases expression |
EXP |
Betaine results in increased expression of KLF10 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994
|
|
G |
Krt2 |
keratin 2 |
increases expression |
EXP |
Betaine results in increased expression of KRT2 mRNA; Betaine results in increased expression of KRT2 protein |
CTD |
PMID:26391144 |
|
NCBI chr 7:132,941,275...132,947,963
Ensembl chr 7:132,940,862...132,947,963
|
|
G |
Krt4 |
keratin 4 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of KRT4 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:133,046,067...133,052,027
Ensembl chr 7:133,046,515...133,052,019
|
|
G |
Lars1 |
leucyl-tRNA synthetase 1 |
decreases expression |
EXP |
Betaine results in decreased expression of LARS mRNA |
CTD |
PMID:26391144 |
|
NCBI chr18:34,201,555...34,256,003
Ensembl chr18:34,201,549...34,255,931
|
|
G |
Lepr |
leptin receptor |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of LEPR mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lin9 |
lin-9 DREAM MuvB core complex component |
decreases expression |
EXP |
Betaine results in decreased expression of LIN9 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr13:92,374,612...92,419,664
Ensembl chr13:92,374,593...92,419,654
|
|
G |
Lratd1 |
LRAT domain containing 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of LRATD1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 6:36,916,969...36,922,143
Ensembl chr 6:36,913,469...36,922,319
|
|
G |
Lrrc24 |
leucine rich repeat containing 24 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of LRRC24 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:108,437,296...108,444,561
Ensembl chr 7:108,437,296...108,444,438
|
|
G |
Map4k1 |
mitogen activated protein kinase kinase kinase kinase 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of MAP4K1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:84,270,951...84,292,496
Ensembl chr 1:84,271,069...84,292,493
|
|
G |
Marchf6 |
membrane associated ring-CH-type finger 6 |
multiple interactions decreases stability |
ISO |
Cholesterol inhibits the reaction [Betaine results in decreased stability of MARCHF6 protein] |
CTD |
PMID:30545937 |
|
NCBI chr 2:82,455,686...82,532,917
Ensembl chr 2:82,455,689...82,532,910
|
|
G |
Mcm3 |
minichromosome maintenance complex component 3 |
decreases expression |
EXP |
Betaine results in decreased expression of MCM3 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314
|
|
G |
Mcm4 |
minichromosome maintenance complex component 4 |
decreases expression |
EXP |
Betaine results in decreased expression of MCM4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr11:85,258,443...85,272,144
Ensembl chr11:85,258,443...85,272,144
|
|
G |
Mcm5 |
minichromosome maintenance complex component 5 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MCM5 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr19:13,483,030...13,504,389
Ensembl chr19:13,483,066...13,504,389
|
|
G |
Mcm6 |
minichromosome maintenance complex component 6 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MCM6 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
decreases expression |
EXP |
Betaine results in decreased expression of MCM7 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063
|
|
G |
Mical1 |
microtubule associated monooxygenase, calponin and LIM domain containing 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MICAL1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr20:44,974,137...44,986,089
Ensembl chr20:44,974,138...44,986,089
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MKI67 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mthfd1l |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like |
decreases expression |
EXP |
Betaine results in decreased expression of MTHFD1L mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:40,443,926...40,632,911
Ensembl chr 1:40,444,008...40,632,905
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
decreases expression |
EXP |
Betaine results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
EXP |
Betaine inhibits the reaction [Diethylnitrosamine results in increased expression of MYC mRNA] |
CTD |
PMID:19642983 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Mycl |
MYCL proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of MYCL mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 5:135,274,713...135,281,584
Ensembl chr 5:135,274,748...135,281,582
|
|
G |
Nbl1 |
NBL1, DAN family BMP antagonist |
increases expression |
EXP |
Betaine results in increased expression of NBL1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:151,318,752...151,329,948
Ensembl chr 5:151,318,754...151,338,719
|
|
G |
Nckipsd |
NCK interacting protein with SH3 domain |
decreases expression |
EXP |
Betaine results in decreased expression of NCKIPSD mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 8:109,511,484...109,522,625
Ensembl chr 8:109,511,658...109,522,246
|
|
G |
Ndrg4 |
NDRG family member 4 |
decreases expression |
EXP |
Betaine results in decreased expression of NDRG4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr19:9,351,408...9,387,398
Ensembl chr19:9,351,404...9,386,914
|
|
G |
Nlrp12 |
NLR family, pyrin domain containing 12 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of NLRP12 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:65,932,610...65,969,873
Ensembl chr 1:65,932,595...65,960,934
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
decreases expression |
EXP |
Betaine results in decreased expression of NUPR1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:181,213,292...181,215,327
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
multiple interactions |
ISO |
Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased expression of OGG1 protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of OGG1 promoter] |
CTD |
PMID:22064374 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
Pcp4 |
Purkinje cell protein 4 |
increases expression |
EXP |
Betaine results in increased expression of PCP4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr11:35,759,711...35,861,725
Ensembl chr11:35,800,713...35,861,725
|
|
G |
Pctp |
phosphatidylcholine transfer protein |
decreases expression |
EXP |
Betaine results in decreased expression of PCTP mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:74,808,887...74,856,260
Ensembl chr10:74,808,887...74,849,867
|
|
G |
Per2 |
period circadian regulator 2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of PER2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459
|
|
G |
Pola2 |
DNA polymerase alpha 2, accessory subunit |
decreases expression |
EXP |
Betaine results in decreased expression of POLA2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:203,227,183...203,251,350
Ensembl chr 1:203,203,388...203,251,348
|
|
G |
Pole2 |
DNA polymerase epsilon 2, accessory subunit |
decreases expression |
EXP |
Betaine results in decreased expression of POLE2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:87,674,702...87,712,723
Ensembl chr 6:87,674,702...87,699,305
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions decreases expression |
ISO |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of PPARA protein Betaine results in decreased expression of PPARA mRNA |
CTD |
PMID:20118189 PMID:22945834 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppp1r3g |
protein phosphatase 1, regulatory subunit 3G |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of PPP1R3G mRNA |
CTD |
PMID:33549593 |
|
NCBI chr17:28,874,956...28,878,288
Ensembl chr17:28,876,482...28,877,525
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
multiple interactions |
ISO |
Betaine inhibits the reaction [Ethanol results in decreased methylation of PPP2CA protein] |
CTD |
PMID:32492475 |
|
NCBI chr10:36,358,110...36,377,864
Ensembl chr10:36,358,101...36,377,862
|
|
G |
Prss23 |
serine protease 23 |
increases expression |
EXP |
Betaine results in increased expression of PRSS23 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:143,402,725...143,422,182
Ensembl chr 1:143,401,396...143,422,091
|
|
G |
Prss8 |
serine protease 8 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of PRSS8 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:182,536,229...182,540,745
Ensembl chr 1:182,536,229...182,540,815
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
Betaine inhibits the reaction [Azacitidine results in decreased methylation of PSEN1 promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of PSEN1 promoter] |
CTD |
PMID:19635394 |
|
NCBI chr 6:103,323,014...103,375,088
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
decreases expression |
EXP |
Betaine results in decreased expression of PTGS1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ranbp3l |
RAN binding protein 3-like |
decreases expression |
EXP |
Betaine results in decreased expression of RANBP3L mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 2:58,057,887...58,113,158
Ensembl chr 2:58,058,263...58,113,172
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Betaine inhibits the reaction [Fructose results in decreased activity of RELA protein] |
CTD |
PMID:25559852 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rfx4 |
regulatory factor X4 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of RFX4 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:18,853,065...19,015,378
Ensembl chr 7:18,853,322...19,014,967
|
|
G |
Rgs16 |
regulator of G-protein signaling 16 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of RGS16 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr13:65,887,788...65,891,232
Ensembl chr13:65,887,530...65,892,857
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
increases expression |
EXP |
Betaine results in increased expression of RGS2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
decreases expression multiple interactions |
EXP ISO |
Betaine results in decreased expression of RRM2 mRNA [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of RRM2 mRNA |
CTD |
PMID:26391144 PMID:33549593 |
|
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of S100A8 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression |
EXP |
Betaine results in decreased expression of SCD1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Sectm1b |
secreted and transmembrane 1B |
increases expression |
EXP |
Betaine results in increased expression of SECTM1A mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:106,325,202...106,333,769
Ensembl chr10:106,325,203...106,333,769
|
|
G |
Serinc2 |
serine incorporator 2 |
decreases expression |
EXP |
Betaine results in decreased expression of SERINC2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:142,592,308...142,614,628
Ensembl chr 5:142,592,309...142,618,364
|
|
G |
Serpina3n |
serine (or cysteine) peptidase inhibitor, clade A, member 3N |
decreases expression |
EXP |
Betaine results in decreased expression of SERPINA3N mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:123,323,632...123,331,166
Ensembl chr 6:123,323,629...123,332,433
|
|
G |
Slc16a6 |
solute carrier family 16, member 6 |
increases expression |
EXP |
Betaine results in increased expression of SLC16A6 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:94,424,377...94,447,984
Ensembl chr10:94,426,244...94,448,779
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
multiple interactions |
ISO |
Betaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] |
CTD |
PMID:16928358 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc25a30 |
solute carrier family 25, member 30 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of SLC25A30 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr15:51,076,998...51,099,613
Ensembl chr15:51,077,002...51,099,613
|
|
G |
Slc36a1 |
solute carrier family 36 member 1 |
increases uptake |
ISO |
SLC36A1 protein results in increased uptake of Betaine |
CTD |
PMID:18845132 |
|
NCBI chr10:39,319,062...39,357,374
Ensembl chr10:39,324,337...39,354,217
|
|
G |
Slc6a12 |
solute carrier family 6 member 12 |
multiple interactions |
ISO |
Betaine inhibits the reaction [Lipopolysaccharides results in increased expression of SLC6A12 mRNA] |
CTD |
PMID:22053950 |
|
NCBI chr 4:154,585,386...154,603,750
Ensembl chr 4:154,585,500...154,603,750
|
|
G |
Slc6a9 |
solute carrier family 6 member 9 |
decreases expression |
EXP |
Betaine results in decreased expression of SLC6A9 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:131,374,562...131,408,733
Ensembl chr 5:131,374,542...131,408,728
|
|
G |
Snx10 |
sorting nexin 10 |
decreases expression |
EXP |
Betaine results in decreased expression of SNX10 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 4:80,612,648...80,677,005
Ensembl chr 4:80,612,669...80,676,996
|
|
G |
Socs2 |
suppressor of cytokine signaling 2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of SOCS2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548
|
|
G |
Sostdc1 |
sclerostin domain containing 1 |
increases expression |
EXP |
Betaine results in increased expression of SOSTDC1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:53,051,336...53,055,510
Ensembl chr 6:53,051,354...53,055,579
|
|
G |
Spc25 |
SPC25 component of NDC80 kinetochore complex |
decreases expression |
EXP |
Betaine results in decreased expression of SPC25 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:53,930,013...53,988,940
Ensembl chr 3:53,975,704...53,988,959
|
|
G |
Ssr4 |
signal sequence receptor subunit 4 |
decreases expression |
EXP |
Betaine results in decreased expression of SSR4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr X:151,524,191...151,528,218
Ensembl chr X:151,524,009...151,528,202
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP |
Betaine promotes the reaction [Isoproterenol results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:25080425 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stmn1 |
stathmin 1 |
decreases expression |
EXP |
Betaine results in decreased expression of STMN1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154
|
|
G |
Stxbp1 |
syntaxin binding protein 1 |
decreases expression |
EXP |
Betaine results in decreased expression of STXBP1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 3:16,076,725...16,138,431
Ensembl chr 3:16,076,391...16,138,369
|
|
G |
Sult1e1 |
sulfotransferase family 1E member 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of SULT1E1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
increases expression |
EXP |
Betaine results in increased expression of TGFB2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Betaine inhibits the reaction [ATP7B protein mutant form results in increased expression of TNF mRNA] |
CTD |
PMID:22945834 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trib2 |
tribbles pseudokinase 2 |
decreases expression |
EXP |
Betaine results in decreased expression of TRIB2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr 6:38,545,971...38,570,349
Ensembl chr 6:38,545,975...38,569,370
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ULK1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
|
|
G |
Upk3bl1 |
uroplakin 3B like 1 |
decreases expression |
EXP |
Betaine results in decreased expression of UPK3BL1 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr12:20,610,353...20,616,366
Ensembl chr12:20,610,353...20,616,366
|
|
G |
Usp2 |
ubiquitin specific peptidase 2 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of USP2 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 8:44,411,457...44,439,668
Ensembl chr 8:44,411,607...44,438,331
|
|
G |
Vnn1 |
vanin 1 |
multiple interactions |
ISO |
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of VNN1 mRNA |
CTD |
PMID:33549593 |
|
NCBI chr 1:21,537,084...21,547,395
Ensembl chr 1:21,537,094...21,547,395
|
|
G |
Wnk4 |
WNK lysine deficient protein kinase 4 |
decreases expression |
EXP |
Betaine results in decreased expression of WNK4 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:86,202,552...86,219,655
Ensembl chr10:86,188,812...86,231,829
|
|
G |
Ybx2 |
Y box binding protein 2 |
decreases expression |
EXP |
Betaine results in decreased expression of YBX2 mRNA |
CTD |
PMID:26391144 |
|
NCBI chr10:54,659,719...54,665,371
Ensembl chr10:54,659,719...54,665,371
|
|
|
G |
Avp |
arginine vasopressin |
multiple interactions |
EXP |
Hexamethonium promotes the reaction [Dexamethasone results in increased activity of AVP protein] |
CTD |
PMID:3346065 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
affects response to substance |
ISO |
BDKRB2 affects the susceptibility to Hexamethonium |
CTD |
PMID:10614985 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
Hexamethonium affects the reaction [Nicotine results in increased expression of BIRC5 protein] |
CTD |
PMID:16601104 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
ISO |
Hexamethonium inhibits the reaction [Nicotine results in decreased expression of CDK4 protein] |
CTD |
PMID:15231866 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Chrna3 |
cholinergic receptor nicotinic alpha 3 subunit |
multiple interactions |
EXP |
Hexamethonium results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein] |
CTD |
PMID:9687574 |
|
NCBI chr 8:55,401,981...55,415,012
Ensembl chr 8:55,401,702...55,415,165
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
ISO |
Hexamethonium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Hexamethonium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] Hexamethonium inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein] |
CTD |
PMID:7756618 PMID:14645658 |
|
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO |
Hexamethonium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Hexamethonium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] Hexamethonium inhibits the reaction [Nicotine results in increased expression of CHRNB2 protein] |
CTD |
PMID:7756618 PMID:14645658 |
|
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
EXP |
Hexamethonium results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein] |
CTD |
PMID:9687574 |
|
NCBI chr 8:55,418,379...55,436,967
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Hexamethonium inhibits the reaction [Hydrochloric Acid results in increased expression of FOS protein] |
CTD |
PMID:12588467 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Hexamethonium inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK1 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:18448488 PMID:20106947 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Hexamethonium inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK3 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:18448488 PMID:20106947 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
EXP |
Hexamethonium inhibits the reaction [[Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of MKI67 protein] |
CTD |
PMID:29501575 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Npy |
neuropeptide Y |
multiple interactions |
EXP |
Hexamethonium inhibits the reaction [Nicotine results in increased expression of NPY mRNA] |
CTD |
PMID:2233698 |
|
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO EXP |
Hexamethonium inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein] Hexamethonium inhibits the reaction [[Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of STAT3 protein modified form] |
CTD |
PMID:18448488 PMID:20106947 PMID:29501575 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
Hexamethonium affects the reaction [Nicotine results in increased expression of XIAP protein] |
CTD |
PMID:16601104 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Adamts4 |
ADAM metallopeptidase with thrombospondin type 1 motif, 4 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS4 protein] |
CTD |
PMID:32417162 |
|
NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065
|
|
G |
Adamts5 |
ADAM metallopeptidase with thrombospondin type 1 motif, 5 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS5 protein] |
CTD |
PMID:32417162 |
|
NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]; stachydrine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein]; stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of RELA protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS4 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS5 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of TNF protein] |
CTD |
PMID:32417162 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of IL6 protein] |
CTD |
PMID:32417162 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein] |
CTD |
PMID:32417162 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein] |
CTD |
PMID:32417162 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:32417162 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein] |
CTD |
PMID:32417162 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein] |
CTD |
PMID:32417162 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of RELA protein] |
CTD |
PMID:32417162 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
stachydrine inhibits the reaction [IL1B protein results in increased secretion of TNF protein] |
CTD |
PMID:32417162 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Acadl |
acyl-CoA dehydrogenase, long chain |
increases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in increased expression of ACADL mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 9:68,333,981...68,372,149
Ensembl chr 9:68,333,980...68,372,220
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
decreases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of ACADM mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acadvl |
acyl-CoA dehydrogenase, very long chain |
affects expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate affects the expression of ACADVL mRNA |
CTD |
PMID:32389661 |
|
NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
affects expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate affects the expression of ACOX1 mRNA |
CTD |
PMID:32389661 |
|
NCBI chr10:101,406,197...101,431,242
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
decreases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of CPT1B mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Cpt1c |
carnitine palmitoyltransferase 1c |
decreases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of CPT1C mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 1:95,442,814...95,457,347
Ensembl chr 1:95,442,817...95,457,342
|
|
G |
Hk1 |
hexokinase 1 |
increases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in increased expression of HK1 mRNA |
CTD |
PMID:32389661 |
|
NCBI chr20:30,230,488...30,332,161
Ensembl chr20:30,230,486...30,332,131
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
increases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in increased expression of PDK1 mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate affects the expression of PPARA mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression |
EXP ISO |
3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:27559315 PMID:32389661 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
affects expression |
EXP |
3-(2,2,2-trimethylhydrazine)propionate affects the expression of PPARGC1B mRNA |
CTD |
PMID:27559315 |
|
NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
increases uptake |
ISO EXP |
SLC22A5 protein results in increased uptake of 3-(2,2,2-trimethylhydrazine)propionate |
CTD |
PMID:18981167 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
increases expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate results in increased expression of SLC2A4 mRNA |
CTD |
PMID:32389661 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc5a2 |
solute carrier family 5 member 2 |
affects expression |
ISO |
3-(2,2,2-trimethylhydrazine)propionate affects the expression of SLC5A2 mRNA |
CTD |
PMID:32389661 |
|
NCBI chr 1:182,847,185...182,853,309
Ensembl chr 1:182,847,106...182,853,306
|
|
G |
Tfam |
transcription factor A, mitochondrial |
decreases expression |
EXP |
3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of TFAM mRNA |
CTD |
PMID:27559315 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases response to substance |
ISO |
Cyclosporine inhibits the reaction [[AHR protein results in increased susceptibility to Antigens] which results in increased susceptibility to Methacholine Chloride] [AHR protein results in increased susceptibility to Antigens] which results in increased susceptibility to Methacholine Chloride; AHR protein results in increased susceptibility to Methacholine Chloride |
CTD |
PMID:27869817 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Bmpr2 |
bone morphogenetic protein receptor type 2 |
multiple interactions |
ISO |
BMPR2 protein affects the susceptibility to [Methacholine Chloride co-treated with Antigens, Dermatophagoides] |
CTD |
PMID:22427841 |
|
NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809
|
|
G |
C3 |
complement C3 |
multiple interactions |
ISO |
C3 protein affects the susceptibility to [Ozone co-treated with Methacholine Chloride] |
CTD |
PMID:14701711 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
Cacna1e |
calcium voltage-gated channel subunit alpha1 E |
multiple interactions |
EXP |
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid affects the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; Atropine inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; Calcium inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; Heparin affects the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]; Ro 31-8425 inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]] |
CTD |
PMID:12663092 |
|
NCBI chr13:66,574,659...67,063,443
Ensembl chr13:66,581,920...66,894,450
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [Methacholine Chloride promotes the reaction [CFTR protein results in increased export of Chlorides]]; Methacholine Chloride promotes the reaction [CFTR protein results in increased export of Chlorides] |
CTD |
PMID:20675434 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Cpe |
carboxypeptidase E |
increases response to substance |
ISO |
CPE gene mutant form results in increased susceptibility to Methacholine Chloride |
CTD |
PMID:16002559 |
|
NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233
|
|
G |
Cxcr2 |
C-X-C motif chemokine receptor 2 |
multiple interactions |
ISO |
Ozone promotes the reaction [CXCR2 protein affects the susceptibility to Methacholine Chloride] |
CTD |
PMID:15361358 |
|
NCBI chr 9:75,729,493...75,735,868
Ensembl chr 9:75,729,115...75,739,425
|
|
G |
Fcer2 |
Fc epsilon receptor II |
increases expression |
ISO |
Methacholine Chloride results in increased expression of FCER2 protein |
CTD |
PMID:15801332 |
|
NCBI chr12:1,742,809...1,754,476
Ensembl chr12:1,742,815...1,754,476
|
|
G |
Grk3 |
G protein-coupled receptor kinase 3 |
affects response to substance |
ISO |
GRK3 mutant form affects the susceptibility to Methacholine Chloride |
CTD |
PMID:10198406 |
|
NCBI chr12:43,624,778...43,735,375
Ensembl chr12:43,624,897...43,731,262
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
multiple interactions increases expression |
ISO |
IL1RN protein results in decreased susceptibility to [Ozone co-treated with Methacholine Chloride] Methacholine Chloride results in increased expression of IL1RN protein |
CTD |
PMID:14754758 PMID:15801332 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Lep |
leptin |
increases response to substance |
ISO |
LEP gene mutant form results in increased susceptibility to Methacholine Chloride |
CTD |
PMID:12794034 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
NOS2 protein affects the reaction [2-chloroethyl ethyl sulfide affects the susceptibility to Methacholine Chloride] |
CTD |
PMID:22446026 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions decreases response to substance |
ISO |
N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [NOS3 gene mutant form results in decreased susceptibility to Methacholine Chloride] |
CTD |
PMID:22421449 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
NR1I2 protein affects the susceptibility to [5-alpha-Dihydroprogesterone co-treated with Methacholine Chloride] |
CTD |
PMID:17159084 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[hydroquinone results in increased expression of TNF protein] which results in increased susceptibility to Methacholine Chloride; Chlorpromazine inhibits the reaction [[hydroquinone results in increased expression of TNF protein] which results in increased susceptibility to Methacholine Chloride]; Cromolyn Sodium inhibits the reaction [[hydroquinone results in increased expression of TNF protein] which results in increased susceptibility to Methacholine Chloride] |
CTD |
PMID:22414385 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases response to substance |
ISO |
TNFRSF1A protein results in increased susceptibility to Methacholine Chloride |
CTD |
PMID:21070800 |
|
|